Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells

Benyamin Ranjbar(Aarhus University), Jacob Giehm Mikkelsen(Aarhus University), Maria Nascimento Primo(Aarhus University), Karen Dybkær(Aalborg University Hospital), Louise Bechmann Krogh(Aarhus University), Maria Bach Laursen(Chr. Hansen (Denmark)), Sara Correia Marques(Chr. Hansen (Denmark))

PLoS ONE

April 5, 2016

10.1371/journal.pone.0153069

Cited by 4

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication

|Proceedings of the National Academy of Sciences|2013|342